 |
PDBsum entry 6b0v
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Signaling protein
|
PDB id
|
|
|
|
6b0v
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
The reactivity-Driven biochemical mechanism of covalent krasg12c inhibitors.
|
 |
|
Authors
|
 |
R.Hansen,
U.Peters,
A.Babbar,
Y.Chen,
J.Feng,
M.R.Janes,
L.S.Li,
P.Ren,
Y.Liu,
P.P.Zarrinkar.
|
 |
|
Ref.
|
 |
Nat Struct Mol Biol, 2018,
25,
454-462.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Activating mutations in KRAS are among the most common tumor driver mutations.
Until recently, KRAS had been considered undruggable with small molecules; the
discovery of the covalent KRASG12C inhibitors ARS-853 and ARS-1620
has demonstrated that it is feasible to inhibit KRAS with high potency in cells
and animals. Although the biological activity of these inhibitors has been
described, the biochemical mechanism of how the compounds achieve potent
inhibition remained incompletely understood. We now show that the activity of
ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the
chemical reaction with Cys12 in human KRASG12C, while the reversible
binding affinity is weak, in the hundreds of micromolar or higher range. The
mechanism resolves how an induced, shallow and dynamic pocket not expected to
support high-affinity binding of small molecules can nevertheless be targeted
with potent inhibitors and may be applicable to other targets conventionally
considered undruggable.
|
 |
|
|
|
|
 |